188 related articles for article (PubMed ID: 34425759)
21. Marein ameliorates diabetic nephropathy by inhibiting renal sodium glucose transporter 2 and activating the AMPK signaling pathway in db/db mice and high glucose-treated HK-2 cells.
Guo Y; Ran Z; Zhang Y; Song Z; Wang L; Yao L; Zhang M; Xin J; Mao X
Biomed Pharmacother; 2020 Nov; 131():110684. PubMed ID: 33152903
[TBL] [Abstract][Full Text] [Related]
22. Renal SGLT mRNA expression in human health and disease: a study in two cohorts.
Srinivasan Sridhar V; Ambinathan JPN; Kretzler M; Pyle LL; Bjornstad P; Eddy S; Cherney DZ; Reich HN; ;
Am J Physiol Renal Physiol; 2019 Nov; 317(5):F1224-F1230. PubMed ID: 31545924
[TBL] [Abstract][Full Text] [Related]
23. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
[TBL] [Abstract][Full Text] [Related]
24. Tubular overexpression of Gremlin in transgenic mice aggravates renal damage in diabetic nephropathy.
Marchant V; Droguett A; Valderrama G; Burgos ME; Carpio D; Kerr B; Ruiz-Ortega M; Egido J; Mezzano S
Am J Physiol Renal Physiol; 2015 Sep; 309(6):F559-68. PubMed ID: 26155842
[TBL] [Abstract][Full Text] [Related]
25. Intervention for early diabetic nephropathy by mesenchymal stem cells in a preclinical nonhuman primate model.
An X; Liao G; Chen Y; Luo A; Liu J; Yuan Y; Li L; Yang L; Wang H; Liu F; Yang G; Yi S; Li Y; Cheng J; Lu Y
Stem Cell Res Ther; 2019 Dec; 10(1):363. PubMed ID: 31791397
[TBL] [Abstract][Full Text] [Related]
26. Impacts of Diabetes and an SGLT2 Inhibitor on the Glomerular Number and Volume in db/db Mice, as Estimated by Synchrotron Radiation Micro-CT at SPring-8.
Takiyama Y; Sera T; Nakamura M; Ishizeki K; Saijo Y; Yanagimachi T; Maeda M; Bessho R; Takiyama T; Kitsunai H; Sakagami H; Fujishiro D; Fujita Y; Makino Y; Abiko A; Hoshino M; Uesugi K; Yagi N; Ota T; Haneda M
EBioMedicine; 2018 Oct; 36():329-346. PubMed ID: 30322799
[TBL] [Abstract][Full Text] [Related]
27. Renoprotective effect of atorvastatin on STZ-diabetic rats through attenuating kidney-associated dysmetabolism.
Zhou S; Zhao P; Li Y; Deng T; Tian L; Li H
Eur J Pharmacol; 2014 Oct; 740():9-14. PubMed ID: 25008071
[TBL] [Abstract][Full Text] [Related]
28. Expression and cellular distribution of TLR4, MyD88, and NF-κB in diabetic renal tubulointerstitial fibrosis, in vitro and in vivo.
Liu P; Li F; Qiu M; He L
Diabetes Res Clin Pract; 2014 Aug; 105(2):206-16. PubMed ID: 24894085
[TBL] [Abstract][Full Text] [Related]
29. Deletion of heterogeneous nuclear ribonucleoprotein F in renal tubules downregulates SGLT2 expression and attenuates hyperfiltration and kidney injury in a mouse model of diabetes.
Miyata KN; Lo CS; Zhao S; Zhao XP; Chenier I; Yamashita M; Filep JG; Ingelfinger JR; Zhang SL; Chan JSD
Diabetologia; 2021 Nov; 64(11):2589-2601. PubMed ID: 34370045
[TBL] [Abstract][Full Text] [Related]
30. Expression and activity of SGLT2 in diabetes induced by streptozotocin: relationship with the lipid environment.
Albertoni Borghese MF; Majowicz MP; Ortiz MC; Passalacqua Mdel R; Sterin Speziale NB; Vidal NA
Nephron Physiol; 2009; 112(3):p45-52. PubMed ID: 19390222
[TBL] [Abstract][Full Text] [Related]
31. Malignant fibrous histiocytoma amplified sequence 1 alleviates inflammation and renal fibrosis in diabetic nephropathy by inhibiting TLR4.
Lian H; Cheng Y; Wu X
Biosci Rep; 2019 Nov; 39(11):. PubMed ID: 31696221
[TBL] [Abstract][Full Text] [Related]
32. Ameliorative effect of polydatin on hyperglycemia and renal injury in streptozotocin-induced diabetic rats.
Wang L; Huang L; Li N; Miao J; Liu W; Yu J
Cell Mol Biol (Noisy-le-grand); 2019 Sep; 65(7):55-59. PubMed ID: 31880518
[TBL] [Abstract][Full Text] [Related]
33. Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice.
Tanaka S; Sugiura Y; Saito H; Sugahara M; Higashijima Y; Yamaguchi J; Inagi R; Suematsu M; Nangaku M; Tanaka T
Kidney Int; 2018 Nov; 94(5):912-925. PubMed ID: 30021702
[TBL] [Abstract][Full Text] [Related]
34. Sodium glucose cotransporter 2 and the diabetic kidney.
Komala MG; Panchapakesan U; Pollock C; Mather A
Curr Opin Nephrol Hypertens; 2013 Jan; 22(1):113-9. PubMed ID: 23042029
[TBL] [Abstract][Full Text] [Related]
35. Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy.
Ma J; Wu H; Zhao CY; Panchapakesan U; Pollock C; Chadban SJ
Int J Clin Exp Pathol; 2014; 7(2):481-95. PubMed ID: 24551269
[TBL] [Abstract][Full Text] [Related]
36. Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy.
Lin M; Yiu WH; Wu HJ; Chan LY; Leung JC; Au WS; Chan KW; Lai KN; Tang SC
J Am Soc Nephrol; 2012 Jan; 23(1):86-102. PubMed ID: 22021706
[TBL] [Abstract][Full Text] [Related]
37. Salutary effect of pigment epithelium-derived factor in diabetic nephropathy: evidence for antifibrogenic activities.
Wang JJ; Zhang SX; Mott R; Knapp RR; Cao W; Lau K; Ma JX
Diabetes; 2006 Jun; 55(6):1678-85. PubMed ID: 16731830
[TBL] [Abstract][Full Text] [Related]
38. Sodium-glucose cotransporter 2 inhibition attenuates protein overload in renal proximal tubule via suppression of megalin O-GlcNacylation in progressive diabetic nephropathy.
Otomo H; Nara M; Kato S; Shimizu T; Suganuma Y; Sato T; Morii T; Yamada Y; Fujita H
Metabolism; 2020 Dec; 113():154405. PubMed ID: 33069809
[TBL] [Abstract][Full Text] [Related]
39. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.
Yamamoto K; Uchida S; Kitano K; Fukuhara N; Okumura-Kitajima L; Gunji E; Kozakai A; Tomoike H; Kojima N; Asami J; Toyoda H; Arai M; Takahashi T; Takahashi K
Br J Pharmacol; 2011 Sep; 164(1):181-91. PubMed ID: 21410690
[TBL] [Abstract][Full Text] [Related]
40. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells.
Maki T; Maeno S; Maeda Y; Yamato M; Sonoda N; Ogawa Y; Wakisaka M; Inoguchi T
Sci Rep; 2019 Mar; 9(1):4703. PubMed ID: 30886225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
